S&P 500   4,551.68 (-0.51%)
DOW   35,490.69 (-0.74%)
QQQ   380.55 (+0.38%)
AAPL   149.02 (-0.20%)
MSFT   324.64 (+4.69%)
FB   312.98 (-0.90%)
GOOGL   2,940.26 (+5.53%)
TSLA   1,034.68 (+1.60%)
AMZN   3,397.50 (+0.63%)
NVDA   244.73 (-0.99%)
BABA   169.03 (-0.56%)
NIO   39.34 (-2.79%)
CGC   12.79 (-2.89%)
GE   104.01 (-3.19%)
AMD   122.15 (-0.63%)
MU   68.39 (-0.80%)
T   25.11 (-1.02%)
F   15.60 (-2.13%)
ACB   6.82 (-2.99%)
DIS   169.66 (-1.38%)
PFE   42.97 (-1.35%)
BA   206.83 (-1.42%)
AMC   34.65 (-3.88%)
S&P 500   4,551.68 (-0.51%)
DOW   35,490.69 (-0.74%)
QQQ   380.55 (+0.38%)
AAPL   149.02 (-0.20%)
MSFT   324.64 (+4.69%)
FB   312.98 (-0.90%)
GOOGL   2,940.26 (+5.53%)
TSLA   1,034.68 (+1.60%)
AMZN   3,397.50 (+0.63%)
NVDA   244.73 (-0.99%)
BABA   169.03 (-0.56%)
NIO   39.34 (-2.79%)
CGC   12.79 (-2.89%)
GE   104.01 (-3.19%)
AMD   122.15 (-0.63%)
MU   68.39 (-0.80%)
T   25.11 (-1.02%)
F   15.60 (-2.13%)
ACB   6.82 (-2.99%)
DIS   169.66 (-1.38%)
PFE   42.97 (-1.35%)
BA   206.83 (-1.42%)
AMC   34.65 (-3.88%)
S&P 500   4,551.68 (-0.51%)
DOW   35,490.69 (-0.74%)
QQQ   380.55 (+0.38%)
AAPL   149.02 (-0.20%)
MSFT   324.64 (+4.69%)
FB   312.98 (-0.90%)
GOOGL   2,940.26 (+5.53%)
TSLA   1,034.68 (+1.60%)
AMZN   3,397.50 (+0.63%)
NVDA   244.73 (-0.99%)
BABA   169.03 (-0.56%)
NIO   39.34 (-2.79%)
CGC   12.79 (-2.89%)
GE   104.01 (-3.19%)
AMD   122.15 (-0.63%)
MU   68.39 (-0.80%)
T   25.11 (-1.02%)
F   15.60 (-2.13%)
ACB   6.82 (-2.99%)
DIS   169.66 (-1.38%)
PFE   42.97 (-1.35%)
BA   206.83 (-1.42%)
AMC   34.65 (-3.88%)
S&P 500   4,551.68 (-0.51%)
DOW   35,490.69 (-0.74%)
QQQ   380.55 (+0.38%)
AAPL   149.02 (-0.20%)
MSFT   324.64 (+4.69%)
FB   312.98 (-0.90%)
GOOGL   2,940.26 (+5.53%)
TSLA   1,034.68 (+1.60%)
AMZN   3,397.50 (+0.63%)
NVDA   244.73 (-0.99%)
BABA   169.03 (-0.56%)
NIO   39.34 (-2.79%)
CGC   12.79 (-2.89%)
GE   104.01 (-3.19%)
AMD   122.15 (-0.63%)
MU   68.39 (-0.80%)
T   25.11 (-1.02%)
F   15.60 (-2.13%)
ACB   6.82 (-2.99%)
DIS   169.66 (-1.38%)
PFE   42.97 (-1.35%)
BA   206.83 (-1.42%)
AMC   34.65 (-3.88%)

Novartis Stock Forecast, Price & News

$82.88
-1.96 (-2.31 %)
(As of 10/27/2021 03:52 PM ET)
Add
Compare
Today's Range
$82.45
$83.99
50-Day Range
$81.78
$95.14
52-Week Range
$77.04
$98.52
Volume
254,740 shs
Average Volume
1.92 million shs
Market Capitalization
$185.38 billion
P/E Ratio
20.98
Dividend Yield
2.50%
Beta
0.54
30 days | 90 days | 365 days | Advanced Chart
Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.


Novartis logo

About Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
105,794
Year Founded
1996

Sales & Book Value

Annual Sales
$48.66 billion
Cash Flow
$8.17 per share
Book Value
$24.76 per share

Profitability

Net Income
$8.07 billion

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
2,236,739,000
Market Cap
$185.38 billion
Next Earnings Date
1/25/2022 (Estimated)
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

341st out of 1,365 stocks

Pharmaceutical Preparations Industry

153rd out of 667 stocks

Analyst Opinion: 3.1Community Rank: 4.3Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Novartis (NYSE:NVS) Frequently Asked Questions

Is Novartis a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 3 sell ratings, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novartis stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View analyst ratings for Novartis
or view top-rated stocks.

What stocks does MarketBeat like better than Novartis?

Wall Street analysts have given Novartis a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novartis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, January 25th 2022.
View our earnings forecast for Novartis
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) posted its quarterly earnings results on Monday, October, 25th. The company reported $1.71 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.65 by $0.06. The firm had revenue of $13.03 billion for the quarter, compared to the consensus estimate of $13.02 billion. Novartis had a trailing twelve-month return on equity of 25.25% and a net margin of 17.83%. The business's revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.52 EPS.
View Novartis' earnings history
.

How has Novartis' stock been impacted by COVID-19 (Coronavirus)?

Novartis' stock was trading at $82.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVS stock has increased by 1.1% and is now trading at $83.02.
View which stocks have been most impacted by COVID-19
.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Wednesday, January 27th. Investors of record on Friday, March 5th will be given a dividend of $3.3784 per share on Monday, March 15th. This represents a dividend yield of 2.2%. The ex-dividend date of this dividend is Thursday, March 4th. This is a positive change from Novartis's previous annual dividend of $3.04.
View Novartis' dividend history
.

Is Novartis a good dividend stock?

Novartis pays an annual dividend of $2.08 per share and currently has a dividend yield of 2.50%. Novartis has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio of Novartis is 36.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novartis will have a dividend payout ratio of 31.09% next year. This indicates that Novartis will be able to sustain or increase its dividend.
View Novartis' dividend history.

What price target have analysts set for NVS?

11 analysts have issued 1-year price objectives for Novartis' stock. Their forecasts range from $105.00 to $112.00. On average, they anticipate Novartis' stock price to reach $108.50 in the next twelve months. This suggests a possible upside of 30.7% from the stock's current price.
View analysts' price targets for Novartis
or view top-rated stocks among Wall Street analysts.

Who are Novartis' key executives?

Novartis' management team includes the following people:
  • Vasant Narasimhan, Chief Executive Officer
  • Harry Werner Kirsch, Chief Financial Officer
  • John Tsai, Chief Medical Officer
  • Klaus Moosmayer, Chief Ethics Risk & Compliance Officer
  • Bertrand Bodson, Chief Digital Officer

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis CEO Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among Novartis' employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), The Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.46%), Manning & Napier Group LLC (0.09%), Scharf Investments LLC (0.06%), Chevy Chase Trust Holdings Inc. (0.03%), Douglas Lane & Associates LLC (0.03%) and Professional Advisory Services Inc. (0.01%).

Which major investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Chevy Chase Trust Holdings Inc., Douglas Lane & Associates LLC, Confluence Investment Management LLC, Crossmark Global Holdings Inc., Crossmark Global Holdings Inc., Scharf Investments LLC, Narwhal Capital Management, and Scout Investments Inc..

Which major investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, StoneX Group Inc., Kestra Advisory Services LLC, Private Advisor Group LLC, FNY Investment Advisers LLC, Manning & Napier Group LLC, Salem Capital Management Inc., and DAVENPORT & Co LLC.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $83.02.

How much money does Novartis make?

Novartis has a market capitalization of $185.69 billion and generates $48.66 billion in revenue each year. The company earns $8.07 billion in net income (profit) each year or $5.75 on an earnings per share basis.

How many employees does Novartis have?

Novartis employs 105,794 workers across the globe.

Does Novartis have any subsidiaries?

The following companies are subsidiares of Novartis: Admune Therapeutics, Advanced Accelerator Applications, Alcon, Amblyotech, AveXis, CellforCure, Chiron Corporation, CoStim Pharmaceuticals, Corthera, Encore Vision, Endocyte, Fougera Pharmaceuticals, Hexal, Novartis Inflammasome Research, Protez Pharmaceuticals, Selexys Pharmaceuticals Corporation, Spinifex Pharmaceuticals, The Medicines Company, Vedere Bio, Xiidra, and Ziarco.

When was Novartis founded?

Novartis was founded in 1996.

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

Where are Novartis' headquarters?

Novartis is headquartered at LICHTSTRASSE 35, BASEL V8, CH 4056.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at (161) 324-1111 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.